Posts by: Jose Marques Lopes, PhD

News

Treatment of Duchenne muscular dystrophy (DMD) patients with Raxone (idebenone) delays the need for assisted ventilation by three years, new data from a Phase 3 clinical trial show. Trial ... Read more

July 9, 2018July 10, 2018

Potential DMD Therapy Now in Phase 1 Trial, WVE-210201, Likely To Be Named Orphan Drug in EU

News

The Committee for Orphan Medicinal Products (COMP), an arm of the European Medicines Agency (EMA), is recommending that WVE-210201 be designated an orphan drug as a potential Duchenne muscular dystrophy (DMD) ... Read more

June 27, 2018June 27, 2018

UK Agency Renews Early Access Program for Raxone to Treat Duchenne MD

News

People with Duchenne muscular dystrophy (DMD) in the U.K. will continue to have access to Raxone (idebenone) to treat their disease, after the Medicines and Healthcare products Regulatory Agency (MHRA) renewed its ... Read more

June 25, 2018June 25, 2018

Way to Accurately Measure Changes in Ankle Muscles in Myotonic Dystrophy Type 1 May Aid Clinical Trials

News

A quantitative method that can detect changes in ankle muscle strength in patients with myotonic dystrophy type 1 (MD1) was found to be highly accurate, and may work as an ... Read more

June 15, 2018June 15, 2018

Proteins That Regulate Gene with Critical Role in FSHD Development Identified in Study

News

Researchers identified proteins that regulate DUX4, the key gene in facioscapulohumeral muscular dystrophy (FSHD). The results offer a potential therapeutic pathway, they believe. The study, “NuRD and CAF-1-mediated silencing ... Read more

May 30, 2018May 30, 2018

Artificial Muscles May Lead to Personalized Treatments for MD, Study Suggests

News

Researchers have generated skeletal muscle from human stem cells in the laboratory, an achievement that may advance development of treatments and tissue replacement for patients with muscular dystrophy (MD). ... Read more

April 10, 2018April 11, 2018

Genetic Compensation Mechanism Could Aid in Treatment of Muscle Disorders, Study Suggests

News

A genetic compensation mechanism discovered in zebra fish could have implications in the treatment of muscle diseases, a recent study suggests. The study, “Genetic compensation triggered by actin mutation ... Read more

April 2, 2018April 2, 2018

Tamoxifen and Evista Improved Muscle, Other MD Functions in Mouse Study

News

The use of tamoxifen and Evista (raloxifene) improved cardiac, respiratory, and skeletal muscle functions, and increased bone density in a mouse model of muscular dystrophy (MD), research from the Carolinas ... Read more

March 21, 2018March 21, 2018

AMO Pharma’s Myotonic Dystrophy Therapy Improves Cognition and Function, Phase 2 Trial Shows

News

AMO Pharma’s myotonic dystrophy treatment improved patients’ cognition, fatigue and ability to perform daily tasks, a Phase 2 clinical trial showed. The therapy, AMO-02 (tideglusib), also improved patients’ autism symptoms. In addition, it ... Read more

March 14, 2018

Sarepta to Seek Accelerated US Approval of Duchenne MD Therapy Golodirsen

News

Sarepta Therapeutics will seek accelerated U.S. approval of a treatment for a subset of Duchenne muscular dystrophy (DMD) patients. Golodirsen (SRP-4053) is for patients whose disease stems from a deleted part of ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Raxone Delays Assisted Ventilation in DMD Patients by 3 Years, Phase 3 Trial Results Show

Potential DMD Therapy Now in Phase 1 Trial, WVE-210201, Likely To Be Named Orphan Drug in EU

UK Agency Renews Early Access Program for Raxone to Treat Duchenne MD

Way to Accurately Measure Changes in Ankle Muscles in Myotonic Dystrophy Type 1 May Aid Clinical Trials

Proteins That Regulate Gene with Critical Role in FSHD Development Identified in Study

Artificial Muscles May Lead to Personalized Treatments for MD, Study Suggests

Genetic Compensation Mechanism Could Aid in Treatment of Muscle Disorders, Study Suggests

Tamoxifen and Evista Improved Muscle, Other MD Functions in Mouse Study

AMO Pharma’s Myotonic Dystrophy Therapy Improves Cognition and Function, Phase 2 Trial Shows

Sarepta to Seek Accelerated US Approval of Duchenne MD Therapy Golodirsen

Pin It on Pinterest